Eloralintide

Synonyms: Eloralintide, GLP-1/Glucagon receptor agonist, dual incretin agonist

Eloralintide is a synthetic peptide dual agonist designed to activate both the glucagon-like peptide-1 (GLP-1) and glucagon receptors. This investigational compound is being developed for its potential to modulate metabolic pathways, offering a novel approach to weight management and glycemic control. As a high-purity peptide, it is intended for research and development purposes, not for human use.

With a CAS number of 2883634-40-8, Eloralintide represents a promising candidate in the field of metabolic disorders. Its dual agonist activity aims to harness the complementary effects of GLP-1 and glucagon, potentially leading to improved energy expenditure and appetite regulation. Researchers and pharmaceutical developers are exploring its application in obesity and type 2 diabetes therapies, where it may offer advantages over single-receptor agonists.

Produkt-Highlights

• Hohe Reinheit: ≥98% purity (HPLC) ensures reliable and reproducible results in research settings.
• Dual Agonist Mechanism: Activates both GLP-1 and glucagon receptors, offering a comprehensive approach to metabolic regulation.
• Research-Grade Quality: Manufactured under strict quality control, suitable for in vitro and in vivo studies.
• Custom Packaging: Available in various quantities to accommodate different research scales.
• Documentation Support: Comprehensive COA, MSDS, and TDS provided with every order.

Anwendungen

• Metabolic disorder research
• Obesity and weight management studies
• Type 2 diabetes drug development

Technische Daten

Bestellung und Lieferung

• Verpackung: Bulk packaging available upon request
• Mindestbestellmenge: 5 g
• Lieferzeit: Typically 7-10 business days after order confirmation
• Dokumentation: COA, Sicherheitsdatenblatt, Technisches Datenblatt

Angebotsanfrage

• Unsere Adresse: 280 Main Street, Xi’an, Shaanxi, China
• LyvBio GmbH. — E-Mail: info@lyvbio.com